Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study.

Berardi D, Amore M, Keck PE, Troia M, Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44(8):748-54. PubMed PMID: 9798079.

Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-7. PubMed PMID: 12823080.

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.

Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Gatti G, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22(4):419-23. PubMed PMID: 12172343.

Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia.

González-Rodríguez A, Catalán R, Penadés R, Ruiz Cortés V, Torra M, Seeman MV, et al.. Antipsychotic Response Worsens With Postmenopausal Duration in Women With Schizophrenia. J Clin Psychopharmacol. 2016;36(6):580-587. DOI: 10.1097/JCP.0000000000000571. PubMed PMID: 27626286.

Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia.

Emsley R, Fleischhacker WW, Galderisi S, Halpern LJ, McEvoy JP, Schooler NR. Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. BMJ. 2016;354:i4728. DOI: 10.1136/bmj.i4728. PubMed PMID: 27613560.

Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [(18)F]FEPPA.

Hafizi S, Tseng H-H, Rao N, Selvanathan T, Kenk M, Bazinet RP, et al. Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [(18)F]FEPPA. Am J Psychiatry. 2017;174(2):118-124. DOI: 10.1176/appi.ajp.2016.16020171. PubMed PMID: 27609240.

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.

Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-11. DOI: 10.1176/appi.ajp.161.9.1709. PubMed PMID: 15337666.

Psychiatric comorbidities and schizophrenia.

Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402. DOI: 10.1093/schbul/sbn135. PubMed PMID: 19011234.

Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.

Chen W-Y, Lin S-K. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia. J Clin Psychopharmacol. 2016;36(5):492-5. DOI: 10.1097/JCP.0000000000000555. PubMed PMID: 27580495.

Life-Threatening Lupus-Like Syndrome Associated With Clozapine.

Buzina N, Eterović M. Life-Threatening Lupus-Like Syndrome Associated With Clozapine. J Clin Psychopharmacol. 2016;36(5):532-4. DOI: 10.1097/JCP.0000000000000550. PubMed PMID: 27580496.